Drug Profile
Docosahexanoic acid - University of Massachusetts/Cystic Fibrosis Foundation Therapeutics
Alternative Names: DHA - University of Massachusetts/CFFTLatest Information Update: 13 Jan 2022
Price :
$50
*
At a glance
- Originator University of Massachusetts Medical School
- Developer Cystic Fibrosis Foundation Therapeutics; University of Massachusetts Medical School
- Class Antihyperlipidaemics; Docosahexaenoic acids; Eye disorder therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cystic fibrosis
Most Recent Events
- 08 Jun 2010 Phase II/III development is ongoing in USA